Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Feb 22, 2024 8:36pm
95 Views
Post# 35894755

RE:RE:RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout)

RE:RE:RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout)
Remember that it states in the article that you posted is that it reduces the taxable income by the amount accordingly so the company then saves whatever the amount their tax bracket is and that is the amount that the accumulated loss is. Simple accounting and that is how it is applied in business or at least that is how my accountant does it.
Also remember that the accumulated deficit is 450 million Canadian dollars.
It is the same as an rrsp contribution for example which reduces your taxable income by the amount of the contribution in the year that you contribute and you save that amount that applies to your tax bracket.
So even at 50% tax rate the realized savings or value is still only 225 million CANADIAN dollars and that is the amount that an acquirer would consider adding to the value of a BO if indeed they give full value to that amount in a negotiation.which works out to be about 2.81 Canadian dollars per share if we use 80 millions shares outstanding for example.
Anyway enough of that as we already know that numbers are skewed in accounting and moved around to create the most savings for a company.
<< Previous
Bullboard Posts
Next >>